Objective To assess, by socioeconomic setting, the effect of nationwide vaccination against species A rotavirus (RVA) on childhood diarrhoea-related hospitalizations in Mexico.
Diarrhoea-related hospitalizations in children before and after implementation of monovalent rotavirus vaccination in Mexico
RVA vaccines in national immunization programmes in the Americas and Europe -after both vaccines had been found to show high efficacy and safety in clinical trials in these regions. 2 By 2009, the same vaccines had been found to be efficacious in Africa and Asia and WHO therefore expanded its recommendation to include all children worldwide. 2 Nearly 40
countries -most of them high-or middle-income -have introduced an RVA vaccine into their national programmes. Early evaluations after the introduction of these vaccines in highor middle-income countries have shown a drop in hospitalizations for diarrhoea ranging from 33 to 50%. [3] [4] [5] [6] [7] [8] [9] RVA vaccines have appeared to perform less well in low-income countries. [10] [11] [12] The impact of RVA vaccination in different socioeconomic groups within a single country
has not yet been investigated.
The evaluation of the impact of RVA vaccination in "real-world" settings is a public health priority. Although the direct protection conferred by RVA vaccines against RVA infection needs to be assessed, the broader public health benefits of such vaccines may be better appreciated by evaluating the impact of RVA vaccination on hospitalizations for diarrhoea.
The states of Mexico vary in the level of development that they have achieved and this heterogeneity provides a useful opportunity to examine possible differences in the impact of an RVA vaccine across several socioeconomic strata. 13 After the national introduction of a monovalent RVA vaccine in 2007, substantial declines in diarrhoea-related mortality and morbidity among Mexican children were observed. 14, 15 In one study in Mexico, the incidence of hospitalization for diarrhoea was found to have declined since 2007. 16 However, this decline could not be attributed to RVA vaccination unequivocally because at the time "postvaccine" data had only been collected for two years and the incidence of infection with RVA shows considerable inter-annual variation in the absence of any interventions. 16 In this study we describe trends in hospitalization for diarrhoea among young children in Mexico before and after the introduction of RVA vaccination. The primary aims of this analysis were to document the long-term effect of RVA vaccination on diarrhoea-related hospitalizations and to compare the impact of such vaccination in the poorly developed states of Mexico with that seen in the country's more developed states.
Methods

Data sources
All-cause and diarrhoea-related hospitalizations
Monthly data on all-cause and diarrhoea-related hospitalizations among children younger than 5 years were collected -from an electronic database of Mexico's National System for All analyses were performed using SAS version 9.2 (SAS Institute, Chicago, United
Sates of America) and Excel (Microsoft, Redmond, USA).
Results
Coverage
By 2010, a total of 3 830 932 second doses of monovalent RVA vaccine had been administered to the National Centre for Child and Adolescent Health's target population of 4 677 341 children younger than 5 years. This was equal to a national two-dose coverage of 82% (Table 1) . Two-dose coverage was at least 69% across all the age groups and socioeconomic categories that we considered (Table 1 ). In general, coverage was relatively higher among children younger than 24 months and in the states with high or intermediate socioeconomic status.
Diarrhoea-related hospitalizations
Overall trends
Before the introduction of RVA vaccination nationwide, diarrhoea-related hospitalizations were distinctly seasonal in Mexico (Fig. 1) . About 67% of such hospitalizations occurred between the months of December and May -i.e. during the autumn-winter peak of RVA activity in Mexico. 19 In 2008, a moderate decrease in the number of diarrhoea-related hospitalizations was noted among children younger than 12 months -that is, among the first birth cohort that received the RVA vaccine. extended to include all children aged less than 24 months. By 2011, declines were also noted among children between the ages of 24 and 59 months. The number of diarrhoea-related hospitalizations observed among children younger than 5 years in each of the four years following vaccine introduction was substantially less than that observed in any study year before the vaccine was introduced.
Changes in the seasonality of diarrhoea-related hospitalizations were also observed following the introduction of the RVA vaccine. In the prevaccine period, monthly rates of such hospitalizations peaked in January and February (Fig. 1) . However, the monthly rates rates of diarrhoea-related hospitalization were seen in all the age groups that we investigated, the greatest declines were observed among children younger than 24 months (Table 1) .
Among children younger than 5 years, the rates of diarrhoea-related admission to the admissions in 2008 to 2011, respectively. These changes correspond to rate reductions of 40% (P < 0.001), 41% (P < 0.001) and 32% (P < 0.001), respectively (Table 1) . Substantial and significant reductions -ranging from 40 to 51% -were seen in all regions among children younger than 24 months. Although significant reductions were also noted among children between the ages of 24 and 59 months, the corresponding CIs were wider and these reductions represented only about 5% of the overall fall that was observed. In all of the socioeconomic categories and age groups considered, the postvaccine reductions in diarrhoea-related hospitalizations largely occurred during the autumn and winter seasons, which is when hospitalizations peaked in the prevaccine period (Fig. 2, Fig. 3 and Appendix A). The greatest reductions were seen in January in states with high or intermediate socioeconomic status and in February in states with low socioeconomic status (Fig. 3) . Nationwide, the greatest reductions were seen in January across all age groups (Appendix A). During 2008, statistically significant RRs that exceeded 1 were noted in all regions, especially in March and April (Fig. 3) . However, the results of age-stratified analysis 
Estimated national reduction
It was estimated that 16 537 hospitalizations for diarrhoea among children younger than 5 years were averted annually in Mexico between 2008 and 2011 as the result of RVA vaccination ( Table 2 ).
Discussion
After implementation of RVA vaccination in 2007, substantial declines in paediatric admissions for diarrhoea were observed throughout Mexico. Four observations strongly support a role of RVA vaccination in these declines. First, over 90% of the postvaccine reduction was observed over the 6 months of each year -December through May -when two thirds of childhood hospitalizations due to RVA infection are known to occur. 19 Second, the impact was greatest among children who were younger than 24 months -the age group that is most at risk of severe RVA-related disease. 25 Third, the declines appeared to affect each age group after that age group became eligible for RVA vaccination. Fourth, significant declines were recorded in each of the four years that followed the introduction of RVA vaccination. an RVA vaccine was introduced. 27 Since about 40% of Mexican children who were hospitalized with diarrhoea in the prevaccine period were found to be infected with RVA, 18 a 40% reduction in diarrhoea-related hospitalizations after an RVA vaccine is introduced is, presumably, the best result for Mexico that might be expected.
The peak in diarrhoea-related hospitalizations among Mexican children younger than 5 years was delayed by about two months with respect to the prevaccine period following the introduction of the RVA vaccine. In the United States, peak RVA activity was similarly delayed by about 8 weeks after vaccine introduction. 28 These changes in seasonality probably By 2011, most children in this age group had been immunized against RVA and the increase seen in April and May in the three previous years was not observed.
In clinical trials, the efficacy of RVA vaccines was found to be lower in low-income settings than in middle-or high-income settings. [10] [11] [12] Subsequent studies in Latin America have shown that a licensed RVA vaccine contributed to a reduction of 46% in RVA-related hospitalizations in a low-income country as opposed to a reduction of 76 to 94% in three middle-income countries. 27 This disparity is thought to be related to environmental and hostrelated factors that are common to resource-limited settings and either reduce the uptake of oral RVA vaccines or impede the development of a robust immune response -or both. 29 Some of these factors include enteric infections, interference from oral polio vaccine, neutralizing breast milk and transplacental antibodies, undernutrition and comorbidities such as infection with human immunodeficiency virus. 29 In the present study, the reduction in diarrhoea-related hospitalizations was relatively smaller in the Mexican states with lower levels of socioeconomic development, but it was still statistically significant. In addition, in recent trials in Chiapas, the poorest of Mexico's states, the effectiveness of the monovalent RVA vaccine was shown to be as high as that recorded in some middle-and high-income countries. 30 Furthermore, RVA vaccines are expected to have the greatest impact in resourcelimited settings because of the relatively high baseline rates of RVA gastroenteritis found in such settings.
The factors that reduce vaccine effectiveness in Africa and Asia -where RVA vaccination is still being rolled out -generally differ from those encountered in Latin America and may have a greater effect on vaccination success. 29, 31 Ongoing research focusing on strategies to improve vaccine performance -such as delaying breastfeeding at the time of vaccination, increasing the number of doses administered, and giving zinc or probiotic supplements -could prove crucial in maximizing the benefits of RVA vaccines in these settings. 29, 31 Our study has several important limitations. Because RVA testing is rarely conducted at health ministry facilities in Mexico, data on hospitalizations for RVA-specific gastroenteritis were not available. Thus, we cannot confirm that the observed "postvaccine" reductions in hospitalizations for diarrhoea were solely attributable to vaccination against RVA. Nonetheless, the declines occurred primarily during the peak months of RVA activity, 
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